Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Of Australia Accused Of Collusion By U.S. Regulator

This article was originally published in PharmAsia News

Executive Summary

Australia's CSL is being blocked in its attempt to buy U.S.-based Talecris Biotherapeutics Holdings in part because of alleged price manipulation in collusion with another company. The U.S. Federal Trade Commission has filed documents in court to back its case against allowing the CSL-Talecris merger. A U.S. district court judge issued a temporary restraining order against CSL's $3.1 billion acquisition of Talecris, a rival in the blood plasma market. According to the FTC filings, CSL and others have been under investigation for the past eight months as the agency probed irregularities. Among FTC allegations is collusion by many drug companies to monitor competitive information to help restrain output and keep prices up. CSL says it has not engaged in a conspiracy and that its prices are influenced by market factors. (Click here for more
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072098

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel